drugset / Trial / NCT05821933
RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC
Non-randomizedSequentialOpen-labelTreatment
Summary
an open, single-arm, multicenter phase Ib/II study
Timeline
- Start
- 2023-09-07
- Primary completion
- 2025-09-01
- Completion
- 2026-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RC108 | Other / unclassified | — | — |
| Subject | Toripalimab | Monoclonal antibody | — | — |
| Background | Firmonertinib | Small molecule | — | — |